ADMISSION TO BREVETTI+ INVITALIA

Hemera has been awarded the Brevetti+ grant, an incentive for the economic valorization of patents promoted by the Ministry of Enterprises and Made in Italy through the Invitalia Agency. This recognition represents a significant step forward in enhancing the value of our intellectual property rights.

Thanks to these resources, Hemera will be able to strategically leverage the patent, accelerating the development of technological innovations and strengthening its competitiveness in the global market. The benefits provided by the Brevetti+ grant will allow us to invest in research and development, protect our inventions, and enhance commercialization activities, promoting the sustainable growth of our company.

HEMERA SIGNS EXCLUSIVE LICENSE AGREEMENT WITH ISTITUTO CLINICO HUMANITAS

In June, Hemera signed an exclusive license agreement with Humanitas Mirasole S.p.A., which owns a 12.5% share of Hemera’s patents, regarding the rights to industrial exploitation of this share. Three years after filing the Italian patent and two years after filing the European patent, Hemera now holds 100% of the industrial exploitation rights, with 87.5% owned outright and 12.5% under an exclusive license for the duration of the patent.

This agreement represents a significant milestone for our company, especially in light of the upcoming entry of new investors. Full control of the industrial exploitation rights places us in a strategic position to maximize the value of our patent portfolio and strengthen our competitiveness in the market.

PROGRESS OF THE OBSERVATIONAL CLINICAL STUDY

Recruitment and monitoring of patients with complete spinal cord injury continue at the active centers for the observational clinical study, including Niguarda Hospital in Milan, Bergamo Hospital, Villa Beretta in Lecco, and the Humanitas Clinical Institute.

In June, 2 new patients were recruited, bringing the total to 5 patients, with 4 at Niguarda Hospital and 1 at Bergamo Hospital.

Over the past year, there has been a slowdown in the enrollment of patients affected by this rare condition, as confirmed by recent epidemiological research. Clinicians observed a decreasing trend in 2023 in the number of patients with complete sensorimotor spinal cord injuries (ASIA A), while the number of patients with complete motor injuries but with preserved sublesional sensitivity (ASIA B) or incomplete injuries (ASIA C/D) has increased.

All patients involved in the study will be monitored for the next 12 months to collect crucial neurophysiological data and parameters. This data will be essential in better defining the medical-scientific project of the study, which, for the first time in humans with REMaST, will be submitted to the European Medicines Agency (EMA).